Fluvoxamine is the preferred choice when CYP2D6 interactions are a concern in generalized anxiety disorder
When CYP2D6 drug interactions are a significant concern, fluvoxamine should be selected over fluoxetine because it is a relatively weak inhibitor of CYP2D6, whereas fluoxetine is a potent CYP2D6 inhibitor.
Rationale Based on CYP2D6 Interaction Profile
Fluoxetine's Strong CYP2D6 Inhibition
Fluoxetine is a potent inhibitor of CYP2D6 1. The FDA label explicitly warns that fluoxetine inhibits CYP2D6 activity and can make individuals with normal CYP2D6 metabolic activity resemble poor metabolizers 1. This creates substantial risk when co-administered with:
- Drugs with narrow therapeutic indices (flecainide, propafenone, TCAs)
- Antipsychotics (phenothiazines, most atypicals)
- Antiarrhythmics
- Beta-blockers
The clinical impact is significant: co-administration of fluoxetine 20 mg/day with desipramine produces approximately 4-fold elevation in peak plasma desipramine concentrations, and this effect persists for approximately 3 weeks after fluoxetine discontinuation due to norfluoxetine's long half-life 2. Research confirms fluoxetine is among the most potent CYP2D6 inhibitors among SSRIs 3, and genetic polymorphisms further amplify this effect 4.
Fluvoxamine's Minimal CYP2D6 Inhibition
In contrast, fluvoxamine is a relatively weak inhibitor of CYP2D6 5. The FDA label states that in vitro data suggest fluvoxamine is a relatively weak inhibitor of the 2D6 isozyme 5. Clinical studies demonstrate fluvoxamine shows minimal in vivo pharmacokinetic interaction with desipramine 2, confirming its weak CYP2D6 inhibitory effect. The rank order of in vitro potency against CYP2D6 places fluvoxamine among the weakest: paroxetine > fluoxetine > sertraline > fluvoxamine 2.
Important Caveat: Fluvoxamine's Other CYP Interactions
While fluvoxamine is superior for avoiding CYP2D6 interactions, you must be aware that fluvoxamine is a potent inhibitor of CYP1A2 and moderate inhibitor of CYP2C19 and CYP3A4 5, 6. This means:
- Contraindicated with tizanidine and alosetron 5
- Significant interactions with theophylline, warfarin, clozapine, and certain benzodiazepines 5
- Avoid co-administration with drugs metabolized primarily by CYP1A2
Clinical Algorithm for Selection
Choose fluvoxamine when:
- Patient takes medications metabolized by CYP2D6 (beta-blockers, TCAs, antipsychotics, antiarrhythmics)
- Patient is elderly with polypharmacy involving CYP2D6 substrates
- Patient has known CYP2D6 poor metabolizer status
Avoid fluvoxamine when:
- Patient takes theophylline, warfarin, tizanidine, alosetron, or clozapine
- Patient takes medications primarily metabolized by CYP1A2
Efficacy Considerations
Both medications are effective for generalized anxiety disorder. Fluvoxamine has demonstrated efficacy in multiple anxiety disorders including panic disorder, social anxiety disorder, and PTSD 6, 7. The efficacy profiles are comparable, so the decision should be driven primarily by the drug interaction profile when CYP2D6 concerns exist.
Practical Management
If fluvoxamine is selected, monitor for interactions with CYP1A2, CYP2C19, and CYP3A4 substrates 5. Start with standard dosing (50-100 mg/day for anxiety disorders) and titrate based on response 6. The drug is generally well tolerated with nausea being the most common adverse event 6.